Whole-Genome Sequencing Is Accurate for Myeloid Cancers
WEDNESDAY, March 10, 2021 -- A streamlined whole-genome sequencing approach can provide rapid and accurate genomic profiling for acute myeloid leukemia (AML) or myelodysplastic syndromes, according to a study published in the March 11 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2021 Category: Pharmaceuticals Source Type: news
Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 4, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Genetic Mutations May Add to Racial Disparity in Child B-ALL
FRIDAY, Feb. 19, 2021 -- Hispanic/Latino (H/L) children with B-cell acute lymphoblastic leukemia (B-ALL) have an increased incidence of IKZF1 deletion and IGH-CRLF2 translocation, according to a letter to the editor published online Feb. 2 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news
New classification of leukemia subtypes reveals potential of existing drugs
(University Health Network) Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) - called NPM1 - that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 16, 2021 Category: International Medicine & Public Health Source Type: news
Researchers take early step toward leukemia drug therapy
(McMaster University) The team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news
Sinai team builds first model acute myeloid leukemia progression using CRISPR
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2021 Category: Cancer & Oncology Source Type: news
TBI Beats Chemoconditioning for ALL Transplants in Children TBI Beats Chemoconditioning for ALL Transplants in Children
Total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing transplant for acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New maintenance treatment for acute myeloid leukemia prolongs the lives of patients
(Weill Cornell Medicine) Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2021 Category: Cancer & Oncology Source Type: news
New drug combination shows promise as powerful treatment for AML
(Sanford Burnham Prebys Medical Discovery Institute) Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news
Leukemia: New Adverse Event With PARP Inhibitors in Cancer Leukemia: New Adverse Event With PARP Inhibitors in Cancer
Late toxicities in the form of myelodysplastic syndrome and acute myeloid leukemia can occur even a brief exposure to PARP inhibitors, and both are associated with a high mortality rate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news
Key Presentations on Acute Myeloid Leukemia From ASH 2020 Key Presentations on Acute Myeloid Leukemia From ASH 2020
Highlights in acute myeloid leukemia from ASH 2020 include study results for combination therapy in newly diagnosed AML patients with FLT-3, and CPX-351 vs 7 + 3 in older adults with secondary or high-risk-prognosis AML.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news
Oral Azacitidine Benefits Some Older Adults With AML
TUESDAY, Dec. 29, 2020 -- For older patients with acute myeloid leukemia (AML) who are in remission after chemotherapy, those receiving maintenance therapy with the oral formulation of azacitidine (CC-486) versus placebo had longer overall and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2020 Category: Pharmaceuticals Source Type: news
Highlights in Acute Lymphoblastic Leukemia From ASH 2020 Highlights in Acute Lymphoblastic Leukemia From ASH 2020
Key studies from ASH 2020 on acute lymphoblastic leukemia include novel CAR T-cells, antibody-based therapies sequenced with chemotherapy, and residual disease monitoring with peripheral blood.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news
Drug offers hope for acute myeloid leukemia treatment in older adults
A new drug treatment for acute myeloid leukemia improves overall survival in those with the deadly blood cancer by up to 10 months, according to a clinical trial published by the New England Journal of Medicine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 24, 2020 Category: Consumer Health News Source Type: news
